Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data

Dysken, Maurice W.; Guarino, Peter; Vertrees, Julia E.; Asthana, Sanjay; Sano, Mary; Llorente, Maria D.; Pallaki, Muralidhar; Love, Susan; Schellenberg, Gerard D.; McCarten, J. Riley; Malphurs, Julie; Prieto, Susana; Chen, Peijun; Loreck, David; Carney, Sara; Trapp, George A.; Bakshi, Rajbir; Mintzer, Jacobo; Heidebrink, Judith L.; Vidal-Cardona, Ana; Arroyo, Lillian M.; Cruz, Angel R.; Kowall, Neil W.; Chopra, Mohit P.; Craft, Suzanne; Thielke, Stephen; Turvey, Carolyn; Woodman, Catherine; Monnell, Kimberly A.; Gordon, Kimberly; Tomaska, Julie; Vatassery, Govind T.

doi:10.1016/j.jalz.2013.01.014

Cited by 49 publications

(29 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because the average length of treatment for participants was considerably longer than most published trials in patients with similar AD severity, 9 the overall proportion of withdrawals in the current study was somewhat higher. The higher than anticipated withdrawal rates were mostly addressed with the sample size reestimation.…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease

Dysken

Sano

Asthana

et al. 2014

JAMA

Self Cite

496

328

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 79%

“…Details regarding the study design and baseline characteristics of the participants have been previously published. 9 …”

Section: Methodsmentioning

confidence: 99%

Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease

Dysken

Sano

Asthana

et al. 2014

JAMA

Self Cite

496

328

View full text Add to dashboard Cite

“…Further qualitative research is necessary to disentangle the locus of control from optimism/pessimism related to AD among older adults, as the pace of AD research can be accelerated by the belief that medical research can help stave off AD, or halted by pessimism related to failed AD trials. Determining which external LOC (powerful others vs. chance) is most relevant in one in three older adults will also guide outreach and education efforts to highlight innovative AD treatments, 34, 35 non-pharmacological preventive strategies, 36 or both.…”

Section: Discussionmentioning

confidence: 99%

Knowledge and Attitudes in Alzheimer’s Disease in a Cohort of Older African Americans and Caucasians

Howell

Soyinka

Parker

et al. 2015

Am J Alzheimers Dis Other Demen

View full text Add to dashboard Cite

African American participation in Alzheimer’s disease (AD) research studies has been historically low. To determine if older African Americans and Caucasians had different knowledge or attitudes related to AD, we administered the Alzheimer’s Disease Knowledge Scale (ADKS) to 67 older African Americans and 140 older Caucasians in the greater Atlanta area, as well as questions targeting locus of control over general health and AD risks. Older African Americans scored slightly lower on ADKS than older Caucasians, with race only accounting for 1.57 (95% CI 0.57–2.61, p < 0.001) points of difference in a mutli-variate model. Attitudes towards AD were also similar between the two groups, but one in three (35.7%) adults reported control over general health but not AD risks. In addition to enhancing education content in outreach efforts, there is an urgent need to address the perception that future AD risks are beyond one’s own internal control.

show abstract

“…Among eight stereoisomers only α-tocopherol is the most bioactive form in humans due to its fat soluble property thus safeguarding the cell membrane from damage by ROS/RNS. Its main role is in the protection against lipid peroxidation and clinically has been reported to prevent the ischemia and certain neurological diseases [94][95][96] . However, a clinical trial has showed that that daily α-tocopherol dose of 400 IU or more can increase the risk of death and should be avoided.…”

Section: (B) Exogenous Antioxidants In Neurodegenerative Diseasesmentioning

confidence: 99%

“…Dysket et al (2014) [124] showed that mild to moderate AD could be treated with treatment of α-tocopherol. Recently Morris et al (2015) [125] have suggested that γ-tocopherol might have beneficial effects in AD pathology in comparison to α-tocopherol. A pilot trial of vitamin E with coenzyme Q10 in Parkinsons' patients have showed the dose dependent neuroprotective effects of vitamin E and coenzyme Q10 and the proposed highest dose was 2400 mg/day however further studies are required.…”

Section: Evidences For the Beneficial Use Of Antioxidants In Neurodegmentioning

confidence: 99%

Antioxidants as a preventive therapeutic option for age related neurodegenerative diseases

Singh

2015

Ther Targets Neurol Dis

View full text Add to dashboard Cite

Neurodegenerative diseases: an overview -Neurodegenerative disease term illustrate a range of conditions in which primarily neurons get affected or die. Neurons are the building blocks of the central and peripheral nervous system. Neurons could not reproduce or replace themselves with age therefore, when they get damaged or die they cannot be replaced and lead to specific neurodegenerative disease. Few evidences for the presence of stem cells are reported [1] but still it is not understood whether damaged neuron could regenerate or not. The Parkinson's, Alzheimer's, and Huntington's diseases are the most prevalent age related neurodegenerative diseases of central nervous system involving death of specific neuronal population. The treatment of these neurodegenerative diseases might involve the re-supplementation of specific neuronal population with the help of stem cells but researchers and clinicians did not get noticeable success in this approach yet. Millions of people each year are getting affected by these neurodegenerative diseases and the incidences are increasing further significantly with the extended life expectancy. It has been reported by World Health Organisation (2006) that the number of older people of more than 65 years age are expected to increase to approximately 1 billion in 2030 worldwide. Developing countries like India and China will see the largest increase in numbers of aged persons. Therefore the percentage of aged population in developing countries would increase from 59% to 71% worldwide [2] . Since occurrence of most of the neurodegenerative Advances in our understanding for neurodegenerative mechanisms have increased significantly in last few decades. But still no novel disease modifying therapy has been developed which could prevent the disease progression and drawn our attention towards the development of new alternative therapy. The major obstacle for the development of disease therapy is incomplete knowledge about neurodegenerative mechanisms. Due to the insufficient information about neurodegenerative mechanisms no standard diagnostic tests for the detection of neurodegenerative disease could be develop to date, causes delayed diagnosis and disease worsening. So far the exploratory reports and clinical data have suggested the involvement of oxidative stress, mitochondrial impairment and apoptosis as major neurodegenerative mechanisms. Investigations have elicited that once initiated the degeneration of neurons could not be arrested therefore in the scarcity of curative therapy we should approach for the preventive neurodegenerative therapy. Since oxidative stress has noteworthy involvement in neuronal death solely, and in connection to other death pathways therefore, antioxidants as preventive therapeutics might provide beneficial effects in age related neurodegenerative diseases. With this hypothesis in this review we are discussing about the use of antioxidants as a preventive treatment of neurodegenerative diseases. Such therapies may work in the preventive phase or in curati...

show abstract

Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data

Cited by 49 publications

References 43 publications

Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease

Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease

Knowledge and Attitudes in Alzheimer’s Disease in a Cohort of Older African Americans and Caucasians

Antioxidants as a preventive therapeutic option for age related neurodegenerative diseases

Contact Info

Product

Resources

About